📄 cardiovascular medicine

MRI-Derived Fat Depots and Cardiometabolic Pathways Underlying Heart Failure Risk: A Mendelian Randomization Study

This Mendelian randomization study reveals that MRI-derived abdominal subcutaneous adipose tissue, unlike conventional anthropometric measures like BMI, captures a distinct cardiometabolic pathway to heart failure risk that is largely mediated by type 2 diabetes, blood pressure, and lipid profiles.

Original authors: Sharma, P., Levin, M.

Published 2026-07-10

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Sharma, P., Levin, M.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your body is a massive, bustling city. For years, doctors have used a single, rough map to judge the city's health: the Body Mass Index (BMI). Think of BMI as a simple drone photo that just counts how many buildings there are in total. It tells you if the city is "big," but it can't tell you where the buildings are or what kind of factories are running inside them.

A new study by researchers Pranav Sharma and Michael G. Levin suggests this old map is missing the most important details. They used a high-tech "genetic time machine" (a method called Mendelian randomization) to peek into the future and see which specific parts of the body actually drive heart failure. Instead of just counting total buildings, they used MRI scans to look at three distinct neighborhoods of fat: the deep, dangerous "visceral" fat (VAT) hiding around the organs, the "gluteofemoral" fat (GFAT) on the hips and thighs, and the "abdominal subcutaneous" fat (ASAT) sitting just under the skin of the belly.

Here is the twist: The study found that the deep, scary visceral fat (VAT) showed a positive link to heart failure, but the data was too fuzzy to be certain about the strength of that connection. Meanwhile, the hip fat (GFAT) was completely innocent, showing no connection at all. The surprise hero (or perhaps villain, depending on how you look at it) was the abdominal subcutaneous fat (ASAT). This is the fat you can pinch on your stomach.

The researchers discovered that having more of this specific "pinchable" belly fat is strongly linked to a higher risk of heart failure. In fact, for every standard increase in this fat, the risk of heart failure jumps by 1.64 times (with a confidence range of 1.40 to 1.93). This is a solid, statistically significant finding, whereas the other fat types were either unclear or showed no link.

But here is the most fascinating part: how does this fat cause trouble? The study acted like a detective, tracing the path from fat to heart failure. They found that ASAT doesn't attack the heart directly. Instead, it acts like a factory manager that hires a team of troublemakers: Type 2 Diabetes, high blood pressure, low "good" cholesterol (HDL), and high triglycerides.

The study suggests that 67.9% (with a range of 49.2% to 86.8%) of the danger caused by this specific belly fat is actually delivered through these metabolic troublemakers. It's as if the fat itself isn't the bomb; it's the fuse that lights the fuse of diabetes and blood pressure, which then blows up the heart.

In contrast, the old-school BMI measurement is like a blurry photo that mixes all these neighborhoods together. While BMI is definitely linked to heart failure (increasing risk by 1.65 times), the study suggests that only a tiny sliver of that risk—about 8.5% (ranging from -7.4% to 24.4%)—is explained by the same metabolic troublemakers. This implies that BMI might be capturing other, messier ways that extra weight hurts the heart, like simply making the heart work harder to pump blood through a larger body, or causing inflammation in ways the study didn't measure.

The researchers are careful to note that their "genetic time machine" had some limits. Because the MRI data came from a smaller group of people (about 38,965 participants) compared to the massive BMI studies (nearly 700,000 people), the clues for the deep visceral fat were a bit fuzzy and imprecise. Also, the data mostly represents people of European ancestry, so we can't be sure if these rules apply perfectly to everyone.

So, what does this mean? The study suggests that if we want to understand heart failure risk, we might need to stop just looking at the total "size" of the city (BMI) and start looking at the specific "pinchable" neighborhood (ASAT). This specific fat depot seems to be a clearer signal for the metabolic syndrome that leads to heart failure. While this doesn't solve the problem of heart failure today, it suggests that in the future, doctors might use routine scans to spot this specific fat depot, helping them target treatments like new diabetes or blood pressure drugs to the people who need them most.

Technical Summary: MRI-Derived Fat Depots and Cardiometabolic Pathways Underlying Heart Failure Risk

Problem Statement
Obesity is a well-established, modifiable risk factor for heart failure (HF), yet the standard clinical metric, body mass index (BMI), fails to distinguish between biologically distinct fat depots. While BMI captures overall adiposity, it does not account for the anatomic distribution of fat, which may drive different cardiometabolic mechanisms. It remains uncertain whether imaging-derived adipose tissue depots capture specific cardiometabolic pathways underlying HF risk that are distinct from or more precise than conventional anthropometric measures.

Methodology
The authors employed a two-sample Mendelian randomization (MR) framework to investigate causal relationships between adiposity traits and HF.

Data Sources:
- Exposures: General adiposity traits (BMI, waist-to-hip ratio [WHR], and WHR adjusted for BMI) were derived from GIANT and UK Biobank meta-analyses (up to 694,649 individuals). MRI-derived fat depots—visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (ASAT), and gluteofemoral adipose tissue (GFAT)—were derived from 38,965 UK Biobank participants.
- Outcome: HF data were obtained from the HERMES consortium (1,946,349 individuals; 153,174 cases).
- Mediators: Cardiometabolic mediators included type 2 diabetes (T2D), systolic blood pressure (SBP), LDL cholesterol, HDL cholesterol, and triglycerides (TG), sourced from their respective largest GWAS.
Analytical Approach:
- Genetic instruments were selected at genome-wide significance ( $P < 5 \times 10^{-8}$ ) with LD clumping.
- Primary analyses utilized inverse-variance weighted (IVW) MR.
- Sensitivity analyses included weighted median, weighted mode, and MR-Egger regression.
- Directionality was assessed via Steiger testing and bidirectional MR.
- Mediation Analysis: Multivariable MR (MVMR) was used to quantify the proportion of each fat trait's effect on HF that operates through the specified cardiometabolic mediators. This was performed using a joint model conditioning simultaneously on significant mediators.

Key Results

Association with HF: Among MRI-derived depots, ASAT was the only trait significantly associated with HF risk (Odds Ratio [OR] 1.64 per 1-SD increase; 95% CI 1.40–1.93; FDR $q < 0.001$ ). VAT showed a positive but imprecise association (OR 1.38; 95% CI 0.87–2.20), and GFAT showed no association. Conventional measures BMI (OR 1.65) and WHR (OR 1.30) were robustly associated with HF, whereas WHR adjusted for BMI was not.
Association with Mediators: ASAT was significantly associated with T2D, SBP, HDL cholesterol, and TG, but not LDL cholesterol. BMI and WHR also showed significant associations with these mediators.
Mediation Analysis:
- ASAT: In joint MVMR, 67.9% (95% CI 49.2–86.8%) of ASAT's effect on HF was mediated through the combined pathways of T2D, SBP, HDL, and TG. This was the only fat trait to achieve statistically significant mediation.
- BMI: Demonstrated only 8.5% mediation (95% CI -7.4 to 24.4%).
- WHR: Showed non-significant mediation of 36.7% (95% CI -8.3 to 81.7%).
- SBP was identified as the dominant mediating pathway across all three fat traits in the joint models.

Significance and Claims
The paper claims that MRI-derived abdominal subcutaneous adipose tissue (ASAT) captures a biologically coherent cardiometabolic signal underlying HF risk that is diluted by conventional anthropometric measures like BMI.

Mechanistic Insight: The authors posit that ASAT functions as an imaging biomarker specifically for metabolic syndrome-mediated HF risk, as the majority of its effect is explained by classical cardiometabolic pathways (T2D, hypertension, dyslipidemia).
Contrast with BMI: In contrast, the HF risk associated with BMI and WHR remains largely unexplained by these same metabolic pathways. The authors suggest BMI and WHR may capture risk mediated by other processes, such as hemodynamic loading, neurohormonal activation, adipokine signaling, and systemic inflammation.
Clinical Implications: The study suggests that quantifying ASAT from routine imaging (MRI or CT) could enable more precise risk stratification and mechanistically targeted prevention. Specifically, the authors propose that enriching clinical trials for emerging cardiometabolic therapies (e.g., GLP-1s, SGLT2s, lipid pathway modulators) with individuals exhibiting ASAT-driven HF risk may be a promising research direction.

Limitations
The authors note several limitations: the MRI-derived exposure GWAS has a smaller sample size (n=38,965) compared to general adiposity GWAS, potentially limiting instrument strength; the data are predominantly of European ancestry; MR assumes lifelong exposure and may not reflect short-term interventions; and the study did not stratify by HF subtypes or sex.

More like this